Should You Buy Moderna Before Feb. 13?

Moderna shares have risen ~39% year-to-date amid positive clinical progress—notably five-year phase‑2 data for the personalized cancer vaccine mRNA‑4157 showing reduced recurrence/death with Keytruda—and a regulatory submission of its influenza candidate mRNA‑1010 for adults 50+. The company expects full‑year 2025 revenue of $1.6–$2.0 billion versus $3.2 billion in 2024 as COVID‑vaccine demand weakens in the U.S.; management will report Q4/2025 results on Feb. 13, which the market should view as unlikely to surprise materially. The stock’s near‑term moves will hinge on execution and regulatory approvals for pipeline assets, making it a longer‑horizon, volatility‑sensitive investment case.

Analysis

Market structure: Moderna (MRNA) is the clear short-term beneficiary of positive readouts for mRNA-4157 and the potential mRNA-1010 flu approval; Merck (MRK) is a secondary beneficiary via co-development economics. Incumbent flu players and lower-efficacy vaccine suppliers face downside risk if mRNA-1010 wins market share among 50+, while COVID booster fatigue continues to depress MRNA's core revenue (2025 guide $1.6–2.0B vs $3.2B in 2024).

Risk assessment: Near-term tail risks are regulatory rejection or an FDA delay of mRNA-1010 and a negative Feb 13 print (days); medium-term risks (3–12 months) include a failed phase‑3 readout for 4157 or manufacturing scale-up problems; long-term (12–36 months) upside depends on approvals and commercial uptake. Hidden dependencies include Merck economics/IP splits and Moderna’s ability to monetize multiple launches simultaneously—failure to commercialize two new launches would compress valuation materially.

Trade implications: For event-driven capital, expect high implied vol into Feb 13 and on regulatory milestones — use hedged, capital‑efficient structures. Idiosyncratic long MRNA exposure is attractive for 12–36 month holders if position size is capped (2–3% of portfolio) and hedged around earnings; pair trades versus broad biotech (XBI) isolate MRNA-specific upside. Cross-asset: positive pipeline news would be modestly risk‑on (tighten HY spreads, push rates down), negative news would widen biotech credit spreads.

Contrarian angle: The market has arguably priced a near-term revenue decline but not a sustained multi-product commercialization pathway; the 39% YTD move looks momentum-driven and may be underpricing commercial execution risk. If MRNA prints revenue < $1.7B on Feb 13 expect a 10–20% downside; conversely, verbal progress on 1010 approval timetables or a clear path for 4157 could re-rate the stock +20% within 3–6 months. Historical parallel: binary clinical catalysts (e.g., early CAR‑T/data-driven re-rates) show big asymmetric outcomes—size positions accordingly.

Key Decisions for Investors

• Establish a capped long core position in MRNA equal to 2–3% of portfolio for 12–36 month exposure to mRNA-1010/4157 commercialization, accepting +/-40% volatility risk around binary milestones.
• Hedge near-term earnings risk before Feb 13: buy 1–2% portfolio notional of 1–3 month puts ~5% OTM and finance by selling 1–2% notional of deeper OTM puts (10–15% OTM) to protect ~50–75% of the core position during the print.
• If bullish on approvals, deploy a 6–9 month call-spread risking no more than 1–2% of portfolio (buy lower-strike/ sell higher-strike) to capture upside from regulatory wins while capping premium spent.
• Implement a pair trade: go long MRNA 2% vs short XBI 2% for 3–6 months to express idiosyncratic MRNA upside while hedging sector weakness; unwind if MRNA revenue prints above $1.9B or below $1.7B (reassess within 48 hours).
• Trigger-based exit: Reduce total MRNA exposure by 50% within 48 hours if company guidance revises 2025 revenue below $1.65B or FDA publicly delays mRNA-1010 review beyond the next 6 months.